

Andrew S Moore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1467066/publications.pdf>

Version: 2024-02-01

65
papers

6,577
citations

218677

26
h-index

123424

61
g-index

69
all docs

69
docs citations

69
times ranked

10761
citing authors

#	ARTICLE	IF	CITATIONS
1	Childhood cancer survival and avoided deaths in Australia, 1983–2016. <i>Paediatric and Perinatal Epidemiology</i> , 2023, 37, 81-91.	1.7	7
2	Changes in cancer incidence and survival among Aboriginal and Torres Strait Islander children in Australia, 1997–2016. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29492.	1.5	2
3	Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions. <i>British Journal of Cancer</i> , 2022, 127, 908-915.	6.4	2
4	Tumor cell invasion into Matrigel: optimized protocol for RNA extraction. <i>BioTechniques</i> , 2021, 70, 327-335.	1.8	0
5	Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10-year review. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29275.	1.5	10
6	Childhood acute myeloid leukemia shows a high level of germline predisposition. <i>Blood</i> , 2021, 138, 2293-2298.	1.4	5
7	Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma. <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	1
8	Second primary cancers in people who had cancer as children: an Australian Childhood Cancer Registry population-based study. <i>Medical Journal of Australia</i> , 2020, 212, 121-125.	1.7	22
9	The incidence of childhood cancer in Australia, 1983–2015, and projections to 2035. <i>Medical Journal of Australia</i> , 2020, 212, 113-120.	1.7	33
10	Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. <i>Nature Medicine</i> , 2020, 26, 1742-1753.	30.7	185
11	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020, 1, 100038.	6.5	24
12	Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective ICBM analysis of 333 children. <i>British Journal of Haematology</i> , 2020, 189, 745-750.	2.5	12
13	Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736. <i>Blood Advances</i> , 2020, 4, 1478-1491.	5.2	15
14	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	9.4	157
15	Invasive fungal infections in children with acute lymphoblastic leukaemia: Results from four Australian centres, 2003–2013. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27915.	1.5	34
16	ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. <i>Communications Biology</i> , 2019, 2, 156.	4.4	73
17	Hematopoietic stem cell transplantation for children with acute myeloid leukemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27812.	1.5	6
18	The Australian and New Zealand Children's Haematology/Oncology Group Biobanking Network. <i>Biopreservation and Biobanking</i> , 2019, 17, 95-97.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Stage at diagnosis for children with blood cancers in Australia: Application of the Toronto Paediatric Cancer Stage Guidelines in a population-based national childhood cancer registry. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27683.	1.5	9
20	Epidemiology of invasive fungal infections in immunocompromised children; an Australian national 10-year review. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27564.	1.5	31
21	<i>PTEN</i> deletion drives acute myeloid leukemia resistance to MEK inhibitors. <i>Oncotarget</i> , 2019, 10, 5755-5767.	1.8	9
22	Assessing the feasibility and validity of the Toronto Childhood Cancer Stage Guidelines: a population-based registry study. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 173-179.	5.6	18
23	The ten-year evolutionary trajectory of a highly recurrent paediatric high grade neuroepithelial tumour with MN1:BEND2 fusion. <i>Scientific Reports</i> , 2018, 8, 1032.	3.3	17
24	Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 389-397.	2.8	25
25	The MLL recombinome of acute leukemias in 2017. <i>Leukemia</i> , 2018, 32, 273-284.	7.2	527
26	Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia. <i>Molecular Cancer Research</i> , 2018, 16, 279-285.	3.4	27
27	Therapy-related acute myeloid leukemia following treatment for cancer in childhood: A population-based registry study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27410.	1.5	12
28	The genetic basis and cell of origin of mixed phenotype acute leukaemia. <i>Nature</i> , 2018, 562, 373-379.	27.8	236
29	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. <i>Nature Medicine</i> , 2018, 24, 1204-1215.	30.7	133
30	Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 15-25.	2.3	10
31	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
32	EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 1779-1787.	7.2	29
33	A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26351.	1.5	20
34	High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. <i>Haematologica</i> , 2017, 102, e490-e493.	3.5	52
35	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. <i>Cancer Cell</i> , 2017, 32, 520-537.e5.	16.8	716
36	Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. <i>Cancer Letters</i> , 2017, 408, 92-101.	7.2	23

#	ARTICLE	IF	CITATIONS
37	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. <i>Oncotarget</i> , 2017, 8, 112036-112050.	1.8	16
38	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016, 30, 891-908.	16.8	191
39	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. <i>Nature Communications</i> , 2016, 7, 11185.	12.8	197
40	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
41	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
42	Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. <i>Oncotarget</i> , 2016, 7, 47465-47478.	1.8	39
43	The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997â€“2008: A report from the Australian Paediatric Cancer Registry. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1664-1666.	1.5	12
44	Targeting Survivin with YM155 (Sepantronium Bromide): A novel therapeutic strategy for paediatric acute myeloid leukaemia. <i>Leukemia Research</i> , 2015, 39, 435-444.	0.8	12
45	Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome. <i>Blood</i> , 2015, 126, 1644-1644.	1.4	2
46	EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia. <i>PLoS ONE</i> , 2015, 10, e0130692.	2.5	20
47	Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells and Delays Relapse following Chemotherapy. <i>Cell Stem Cell</i> , 2014, 15, 775-790.	11.1	74
48	<i>BIRC5</i> (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2014, 61, 647-652.	1.5	27
49	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 1005-1015.	27.0	1,161
50	Novel therapies for children with acute myeloid leukaemia. <i>Leukemia</i> , 2013, 27, 1451-1460.	7.2	47
51	Vincristine sulfate liposomal injection for acute lymphoblastic leukemia. <i>International Journal of Nanomedicine</i> , 2013, 8, 4361.	6.7	18
52	The Survivin Suppressant YM155 (Sepantronium Bromide) Has Potent Pre-Clinical Activity Against Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 3957-3957.	1.4	0
53	Optimization of Imidazo[4,5- <i>b</i>]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8721-8734.	6.4	61
54	Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. <i>Leukemia</i> , 2012, 26, 1462-1470.	7.2	105

#	ARTICLE	IF	CITATIONS
55	A stable-isotope HPLC-MS/MS method to simplify storage of human whole blood samples for glutathione assay. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 898, 136-140.	2.3	17
56	Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited sampling, population modelling approach. <i>Journal of Paediatrics and Child Health</i> , 2011, 47, 875-882.	0.8	53
57	Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia. <i>Leukemia Research</i> , 2011, 35, 1273-1275.	0.8	6
58	Abstract B74: The dual FLT3-Aurora inhibitor CCT241736 overcomes resistance to selective FLT3 inhibition driven by FLT3 ligand and FLT3 point mutations in acute myeloid leukemia.. , 2011, , .		3
59	Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. <i>Leukemia</i> , 2010, 24, 671-678.	7.2	82
60	Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo. <i>Blood</i> , 2010, 116, 3289-3289.	1.4	1
61	Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 Kinases by AT9283 In Children and Adolescents with Leukaemia. <i>Blood</i> , 2010, 116, 1818-1818.	1.4	0
62	Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. <i>Medical Journal of Australia</i> , 2009, 190, 121-125.	1.7	39
63	Localised peripheral primitive neuroectodermal tumour (PNET) of the conjunctiva. <i>Pediatric Blood and Cancer</i> , 2009, 53, 669-671.	1.5	3
64	Vincristine: Can its therapeutic index be enhanced?. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1180-1187.	1.5	63
65	Letters to the Editor. <i>Journal of Paediatrics and Child Health</i> , 2007, 43, 415-416.	0.8	0